兆易創新(603986.SH)一季度淨利潤預增126.12%左右
格隆匯4月14日丨 兆易創新(603986.SH)公佈,預計2022年第一季度實現歸屬於上市公司股東的淨利潤約6.813億元左右,增加3.8億元左右,同比增幅126.12%左右;扣除非經常性損益後,歸屬於上市公司股東的扣除非經常性損益的淨利潤約65022萬元左右,預計增加37335萬元左右,同比增幅134.84%左右。
本季度業績預增主要是由於主營業務的快速增長。受益於公司持續優化產品結構、客户結構,以及多元化供應鏈佈局,公司克服疫情影響,2022年第一季度經營業績大幅增長,實現2022年度良好開局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.